NO20074044L - Meleimidderivater, farmasoytiske preparater og fremgangsmater for behandling av kreft - Google Patents
Meleimidderivater, farmasoytiske preparater og fremgangsmater for behandling av kreftInfo
- Publication number
- NO20074044L NO20074044L NO20074044A NO20074044A NO20074044L NO 20074044 L NO20074044 L NO 20074044L NO 20074044 A NO20074044 A NO 20074044A NO 20074044 A NO20074044 A NO 20074044A NO 20074044 L NO20074044 L NO 20074044L
- Authority
- NO
- Norway
- Prior art keywords
- pyrroloquinolinyl
- methods
- cancer
- meleimide
- dione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Den foreliggende oppfinnelse vedrører pyrrolokinolinylpyrrol-2,5-dionforbindelser og pyrrolokinolinylpyrrolidin-2,5-dionforbindelser, og fremgangsmåter for fremstilling av disse forbindelsene. Den foreliggende oppfinnelse vedrører også farmasøytiske preparater som omfatter pyrrolokinolinylpyrrol-2,5-dionforbindelser og pyrrolokinolinylpyrrolidin-2,5-dionforbindelser. Den foreliggende oppfinnelse tilveiebringer fremgangsmåter for behandling av en celleproliferativ forstyrrelse, slik som en kreftsykdom, ved å administrere til et individ som trenger det, en terapeutisk effektiv mengde av en pyrrolokinolinylpyrrol-2,5-dionforbindelse eller pyrrolokinolinylpyrrolidin-2,5-dionforbindelse ifølge den foreliggende oppfinnelse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65095105P | 2005-02-09 | 2005-02-09 | |
PCT/US2006/004456 WO2006086484A1 (en) | 2005-02-09 | 2006-02-09 | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20074044L true NO20074044L (no) | 2007-10-10 |
NO332635B1 NO332635B1 (no) | 2012-11-26 |
Family
ID=36579999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074044A NO332635B1 (no) | 2005-02-09 | 2007-08-06 | Maleimidderivater, anvendelse derav for fremstilling av et medikament for behandling av kreft og farmasoytiske preparater omfattende derivatene |
Country Status (26)
Country | Link |
---|---|
US (5) | US7713969B2 (no) |
EP (2) | EP2289892B1 (no) |
JP (1) | JP4171061B2 (no) |
KR (1) | KR100941205B1 (no) |
CN (2) | CN101941970B (no) |
AT (1) | ATE486872T1 (no) |
AU (1) | AU2006213890B2 (no) |
BR (1) | BRPI0607240A2 (no) |
CA (1) | CA2599611C (no) |
CY (1) | CY1111190T1 (no) |
DE (1) | DE602006017965D1 (no) |
DK (1) | DK1846406T5 (no) |
ES (1) | ES2354267T3 (no) |
HK (1) | HK1107816A1 (no) |
HR (1) | HRP20100650T2 (no) |
IL (1) | IL184951A (no) |
MX (1) | MX2007009649A (no) |
NO (1) | NO332635B1 (no) |
NZ (1) | NZ560225A (no) |
PL (1) | PL1846406T3 (no) |
PT (1) | PT1846406E (no) |
RS (1) | RS51826B (no) |
RU (3) | RU2409579C2 (no) |
SI (1) | SI1846406T1 (no) |
WO (1) | WO2006086484A1 (no) |
ZA (1) | ZA200706530B (no) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
ZA200706530B (en) | 2005-02-09 | 2009-01-28 | Arqule Inc | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
EP2059802A4 (en) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF |
AU2007336338A1 (en) | 2006-12-19 | 2008-06-26 | Novartis Ag | Indolylmaleimide derivatives as kinase inhibitors |
CN101801961B (zh) * | 2007-06-22 | 2014-09-24 | 艾科尔公司 | 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法 |
NZ581589A (en) * | 2007-06-22 | 2012-10-26 | Scidose Llc | Solubilized sterile injectable formulation of docetaxel without Tween 80 |
AU2008268613A1 (en) | 2007-06-22 | 2008-12-31 | Arqule, Inc. | Quinazolinone compounds and methods of use thereof |
CA2690782C (en) | 2007-06-22 | 2016-02-02 | Arqule, Inc. | Compositions and methods for treatment of cancer |
US7960134B1 (en) | 2007-08-01 | 2011-06-14 | Arqule, Inc. | Kinase inhibition models and their uses |
EP2537529B1 (en) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
EP2211854A4 (en) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS |
JP5739820B2 (ja) | 2008-12-30 | 2015-06-24 | アークル インコーポレイテッド | 置換5,6−ジヒドロ−6−フェニルベンゾ[f]イソキノリン−2−アミン化合物 |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
TWI460178B (zh) * | 2009-02-12 | 2014-11-11 | Arqule Inc | 組合性組成物及治療癌症之方法 |
CA2771774A1 (en) * | 2009-08-21 | 2011-02-24 | Gilead Biologics, Inc. | In vitro screening assays |
AU2010284036B2 (en) | 2009-08-21 | 2014-12-18 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and LOXL2 |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
RU2556205C2 (ru) * | 2009-12-23 | 2015-07-10 | Аркьюл, Инк. | Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения |
US8563567B2 (en) * | 2009-12-30 | 2013-10-22 | Arqule, Inc. | Substituted heterocyclic compounds |
CN103370080A (zh) | 2010-02-04 | 2013-10-23 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法 |
US20130045203A1 (en) * | 2010-03-02 | 2013-02-21 | Emory University | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
US8580764B2 (en) | 2010-07-01 | 2013-11-12 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
EP2611443A2 (en) | 2010-09-01 | 2013-07-10 | ArQule, Inc. | Methods for treatment of non-small cell lung cancer |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
US8470786B2 (en) | 2010-12-23 | 2013-06-25 | Arqule, Inc. | Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
CA2839584A1 (en) | 2011-07-07 | 2013-01-10 | Arqule, Inc. | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same |
CN104379144A (zh) * | 2012-04-23 | 2015-02-25 | 艾科尔公司 | 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法 |
CN102757435B (zh) * | 2012-06-21 | 2014-05-28 | 成都苑东药业有限公司 | 一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法 |
WO2014098000A1 (en) * | 2012-12-17 | 2014-06-26 | Daiichi Sankyo Company, Limited | Process for preparation of a tricyclic heterocycle |
EP3015468A4 (en) * | 2013-06-26 | 2017-02-22 | Daiichi Sankyo Co., Ltd. | Method for producing tricyclic heterocyclic compound |
US9603836B2 (en) | 2014-05-15 | 2017-03-28 | Iteos Therapeutics | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors |
MX2017011951A (es) | 2015-03-17 | 2018-06-15 | Pfizer | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. |
EP3334733A1 (en) | 2015-08-10 | 2018-06-20 | Pfizer Inc | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
US10874130B2 (en) | 2015-08-18 | 2020-12-29 | PURE CIRCLE USA Inc. | Steviol glycoside solutions |
KR20190104359A (ko) * | 2016-12-30 | 2019-09-09 | 프리퀀시 테라퓨틱스, 인크. | 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US650951A (en) | 1899-08-09 | 1900-06-05 | Fred Holmes Rees | Station-indicator. |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
USRE36736E (en) | 1989-02-06 | 2000-06-13 | Hoffman-La Roche Inc. | Substituted pyrroles |
GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
MC2096A1 (fr) | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
CA2015996C (en) | 1989-05-05 | 2001-08-28 | Hartmut Osswald | Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals |
US5380746A (en) | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
DE4005969A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
US5360811A (en) * | 1990-03-13 | 1994-11-01 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents |
US5292747A (en) | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
US5591842A (en) | 1991-11-29 | 1997-01-07 | Banyu Pharmaceutical Co., Ltd. | Indolopyrrolocarbazole derivatives |
AU3761393A (en) | 1992-03-20 | 1993-10-21 | Wellcome Foundation Limited, The | Indole derivatives with antiviral activity |
US5721230A (en) | 1993-05-10 | 1998-02-24 | Hoffmann-La Roche Inc. | Substituted pyrroles |
SI0817627T1 (no) | 1993-12-23 | 2005-08-31 | Lilly Co Eli | |
US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
WO1995030682A1 (fr) | 1994-05-09 | 1995-11-16 | Banyu Pharmaceutical Co., Ltd. | Derive d'indolopyrolocarbazole antitumoral |
US7501441B1 (en) * | 1994-09-20 | 2009-03-10 | Eli Lilly And Company | Naphthyl compounds, intermediates, processes, compositions, and methods |
US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5559228A (en) | 1995-03-30 | 1996-09-24 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
BR9710648A (pt) | 1996-03-20 | 1999-08-17 | Lilly Co Eli | S¡ntese de indolilmaleimidas |
PE91698A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
PE91598A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
CN1228082A (zh) | 1996-08-23 | 1999-09-08 | 伊莱利利公司 | 双吲哚基马来酰亚胺的合成 |
SE9603283D0 (sv) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
US6153618A (en) | 1996-10-11 | 2000-11-28 | Chiron Corporation | Inhibitors of glycogen synthase 3 kinase |
US5859261A (en) | 1997-03-20 | 1999-01-12 | Eli Lilly And Company | Synthesis of indolylmaleimides |
AU746126B2 (en) * | 1997-09-08 | 2002-04-18 | Georgetown University | Substituted 2-pyrrolidinone activators of PKC |
TW380295B (en) * | 1997-10-18 | 2000-01-21 | United Microelectronics Corp | Manufacturing method for DRAM capacitor dielectric |
ID27510A (id) | 1998-07-30 | 2001-04-12 | Japan Tobacco Inc | Senyawa malimida tersubstitusi dan penggunaan farmasinya |
AU2327700A (en) | 1999-02-09 | 2000-08-29 | Rei Asakai | Pyrrole derivatives and cell death inhibitors |
ES2220585T3 (es) | 1999-12-16 | 2004-12-16 | Eli Lilly And Company | Agentes y procedimiento para el tratamiento de enfermedades proliferativas. |
AU2072201A (en) | 1999-12-16 | 2001-06-25 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
WO2001074807A1 (fr) | 2000-03-30 | 2001-10-11 | Sagami Chemical Research Center | Derives indolylpyrrole et inhibiteurs de mort cellulaire |
DE60129222T2 (de) | 2000-05-11 | 2008-03-06 | Consejo Superior de Investigaciónes Científicas | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 |
AU2001277854B2 (en) | 2000-06-29 | 2007-03-01 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
CA2491995A1 (en) | 2001-07-15 | 2003-01-30 | Lori K. Van Ness | Exponential nucleic acid amplification using nicking endonucleases |
CA2473853A1 (en) | 2002-01-23 | 2003-08-14 | J. Suzanne Lindsey | Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells |
ES2276048T3 (es) | 2002-03-05 | 2007-06-16 | Eli Lilly And Company | Derivados de purina como inhibidores de cinasa. |
EP1620573A4 (en) | 2003-04-15 | 2006-12-20 | Avalon Pharmaceuticals | DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
PL1636593T3 (pl) | 2003-06-06 | 2009-08-31 | Genentech Inc | Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. |
ATE451115T1 (de) | 2003-07-07 | 2009-12-15 | Van Andel Res Inst | Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors |
JP2008507252A (ja) | 2003-12-11 | 2008-03-13 | ジェネンテック・インコーポレーテッド | C−met二量体化及び活性化を阻害するための方法と組成物 |
ZA200706530B (en) | 2005-02-09 | 2009-01-28 | Arqule Inc | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
ES2440953T3 (es) | 2005-03-31 | 2014-01-31 | The General Hospital Corporation | Modulación de la actividad de HGF/HGFR para tratar un linfedema |
RU2556205C2 (ru) * | 2009-12-23 | 2015-07-10 | Аркьюл, Инк. | Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения |
CA2839584A1 (en) * | 2011-07-07 | 2013-01-10 | Arqule, Inc. | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same |
-
2006
- 2006-02-09 ZA ZA200706530A patent/ZA200706530B/xx unknown
- 2006-02-09 DE DE602006017965T patent/DE602006017965D1/de active Active
- 2006-02-09 NZ NZ560225A patent/NZ560225A/en unknown
- 2006-02-09 MX MX2007009649A patent/MX2007009649A/es active IP Right Grant
- 2006-02-09 CN CN2010102637660A patent/CN101941970B/zh active Active
- 2006-02-09 PT PT06720509T patent/PT1846406E/pt unknown
- 2006-02-09 CA CA2599611A patent/CA2599611C/en active Active
- 2006-02-09 EP EP10172543A patent/EP2289892B1/en active Active
- 2006-02-09 SI SI200630867T patent/SI1846406T1/sl unknown
- 2006-02-09 RU RU2007131428/04A patent/RU2409579C2/ru active
- 2006-02-09 CN CN200680006758XA patent/CN101133055B/zh active Active
- 2006-02-09 ES ES06720509T patent/ES2354267T3/es active Active
- 2006-02-09 PL PL06720509T patent/PL1846406T3/pl unknown
- 2006-02-09 RS RS20110040A patent/RS51826B/en unknown
- 2006-02-09 BR BRPI0607240-2A patent/BRPI0607240A2/pt not_active IP Right Cessation
- 2006-02-09 US US11/350,335 patent/US7713969B2/en active Active
- 2006-02-09 EP EP06720509A patent/EP1846406B9/en active Active
- 2006-02-09 WO PCT/US2006/004456 patent/WO2006086484A1/en active Application Filing
- 2006-02-09 KR KR1020077020005A patent/KR100941205B1/ko active IP Right Grant
- 2006-02-09 DK DK06720509.6T patent/DK1846406T5/da active
- 2006-02-09 JP JP2007554342A patent/JP4171061B2/ja active Active
- 2006-02-09 AU AU2006213890A patent/AU2006213890B2/en active Active
- 2006-02-09 AT AT06720509T patent/ATE486872T1/de active
- 2006-02-09 RU RU2010135836/04A patent/RU2547148C2/ru active
-
2007
- 2007-07-31 IL IL184951A patent/IL184951A/en active IP Right Grant
- 2007-08-06 NO NO20074044A patent/NO332635B1/no unknown
-
2008
- 2008-02-11 HK HK08101518.3A patent/HK1107816A1/xx unknown
-
2010
- 2010-03-11 US US12/722,394 patent/US8377927B2/en active Active
- 2010-11-26 HR HR20100650T patent/HRP20100650T2/hr unknown
-
2011
- 2011-01-04 CY CY20111100020T patent/CY1111190T1/el unknown
-
2013
- 2013-02-07 US US13/761,712 patent/US8754078B2/en active Active
-
2014
- 2014-03-17 US US14/215,852 patent/US9447088B2/en active Active
-
2015
- 2015-02-10 RU RU2015104346A patent/RU2015104346A/ru not_active Application Discontinuation
-
2016
- 2016-08-19 US US15/241,240 patent/US20160355515A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074044L (no) | Meleimidderivater, farmasoytiske preparater og fremgangsmater for behandling av kreft | |
NO2017019I1 (no) | Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
EA200700501A1 (ru) | Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества | |
LTC1934174I2 (lt) | Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui | |
EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
WO2007048002A3 (en) | Camptothecin derivatives as chemoradiosensitizing agents | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
MX2011006959A (es) | Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina. | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
WO2005110994A3 (en) | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | |
TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
MX2009013815A (es) | Compuestos de quinazolinona y metodos de uso para los mismos. | |
ATE522531T1 (de) | Indolylpyrrolidine zur behandlung von krebs | |
ATE522500T1 (de) | Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür | |
ATE538105T1 (de) | Substituierte tetrazolverbindungen und ihre verwendung | |
NO20054723L (no) | Behandling av proliferative sykdommer med epofilonderivater og straling | |
NO20076075L (no) | 4-anilino-3-kinolinkarbonitriler for behandling av cancer | |
MY140324A (en) | Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer | |
MY148385A (en) | Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer | |
DE60309926D1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung | |
EA201990219A3 (ru) | Ингибиторы mek и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ARQULE INC., US |